ArticleBMC cancer2025
KAT2A: a prognostic biomarker influencing proliferation and immune escape in lung adenocarcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-translational protein lactylation modification in lung cancer: an emerging targeted therapeutic strategy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer, characterized by high mortality rates. KAT2A has been implicated in oncogenic processes and tumor progression. This study systematically investigated the role of KAT2A in LUAD through comprehensive analyses. Expression profiles and prognostic significance of KAT2A were evaluated using TCGA database and multiple GEO datasets. Functional enrichment analyses including GO and KEGG pathway analyses were conducted to elucidate biological mechanisms associated with KAT2A-regulated differentially expressed genes. Correlations between KAT2A expression levels and immune cell infiltration were analyzed using R software and publicly available databases. Experimental validation was performed through CCK-8 assays, colony formation assays, flow cytometry, and xenograft tumor models. Our findings demonstrated significantly elevated KAT2A expression in LUAD tissues and cells. Expression levels correlated with multiple clinicopathological parameters including TNM stage, pathological stage, sex, and tumor localization. High KAT2A expression was associated with reduced overall survival and exhibited prognostic relevance across diverse clinical subgroups. Multivariate analysis confirmed independent prognostic value of KAT2A expression in the established nomogram model. Functional annotation revealed enrichment of KAT2A-associated genes in critical biological processes and signaling pathways. Moreover, KAT2A expression exhibited correlations with mutational profiles and immune cell infiltration patterns in LUAD. Both in vitro and in vivo experiments demonstrated that KAT2A knockdown significantly suppressed tumor cell proliferation and immune evasion mechanisms, induced apoptosis, and inhibited tumor growth. These findings suggest that KAT2A may serve as a potential prognostic biomarker for LUAD, with therapeutic implications through its regulatory role in immune evasion pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.